Kymera Therapeutics KYMR Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kymera Therapeutics's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kymera Therapeutics's net change in cash?
- Kymera Therapeutics (KYMR) reported net change in cash of -$212.91M in Q1 2026.
- How has Kymera Therapeutics's net change in cash changed year-over-year?
- Kymera Therapeutics's net change in cash decreased by 603.2% year-over-year, from -$30.28M to -$212.91M.
- What is the long-term trend for Kymera Therapeutics's net change in cash?
- Over 2 years (2023 to 2025), Kymera Therapeutics's net change in cash has grown at a 139.6% compound annual growth rate (CAGR), from $41.25M to $236.76M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.